MediWound (NASDAQ:MDWD) Stock Price Passes Below 200-Day Moving Average – Here’s Why

MediWound Ltd. (NASDAQ:MDWD)’s share price crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $17.61 and traded as low as $16.15. MediWound shares last traded at $16.25, with a volume of 53,976 shares traded.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Wall Street Zen downgraded shares of MediWound from a “hold” rating to a “strong sell” rating in a research report on Saturday, March 7th. Weiss Ratings restated a “sell (d-)” rating on shares of MediWound in a research report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, MediWound has a consensus rating of “Hold” and an average target price of $35.00.

MediWound Stock Performance

The company’s fifty day simple moving average is $16.89 and its two-hundred day simple moving average is $17.61. The stock has a market capitalization of $208.81 million, a PE ratio of -7.74 and a beta of 0.21.

MediWound (NASDAQ:MDWD) last posted its earnings results on Saturday, February 14th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter. MediWound had a negative net margin of 140.80% and a negative return on equity of 65.79%. The business had revenue of $1.87 million for the quarter. Sell-side analysts forecast that MediWound Ltd. will post -2.75 EPS for the current fiscal year.

Institutional Investors Weigh In On MediWound

Hedge funds have recently modified their holdings of the company. Quarry LP acquired a new stake in shares of MediWound during the 4th quarter worth about $26,000. BNP Paribas Financial Markets boosted its stake in shares of MediWound by 90.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 723 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in shares of MediWound by 69.1% during the 2nd quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 649 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of MediWound by 22.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 999 shares during the last quarter. Finally, MetLife Investment Management LLC acquired a new stake in shares of MediWound during the 4th quarter worth about $109,000. 46.83% of the stock is owned by institutional investors and hedge funds.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.